Bandelow, Borwin

[["dc.bibliographiccitation.firstpage","948"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","The Canadian Journal of Psychiatry"],["dc.bibliographiccitation.lastpage","952"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Tichauer, G. A."],["dc.contributor.author","Spath, C."],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:20:34Z"],["dc.date.available","2018-11-07T11:20:34Z"],["dc.date.issued","2001"],["dc.description.abstract","Objective: The association between separation anxiety in childhood and actual separation experiences during childhood has not yet been investigated in patients with panic disorder. Methods: In 115 patients with panic disorder with or without agoraphobia and in 124 control subjects without a history of psychiatric illness, we assessed separation anxiety during childhood, retrospectively, using DSM-IV and ICD-10 criteria and the Separation Anxiety Symptom Inventory (SASI). In addition, actual separation experiences from age 0 to 15 years were assessed, retrospectively. Results: A total of 22.6% of the patients and 4.8% of the Control subjects fulfilled both DSM-IV and ICD-10 criteria for childhood separation anxiety (chi(2) = 11.8; P < 0.0001). Further, 57.4% ofthepatients and 37.9% of the control subjects reported actual separation experiences during their childhood (chi(2) = 9. 09, P < 0.003). Separation anxiety and actual separation experiences, however, were independent of each other. Conclusion: These results suggest that separation anxiety during childhood is not a consequence of actual traumatic separation experiences in panic disorder patients."],["dc.identifier.isi","000173099800007"],["dc.identifier.pmid","11816316"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55564"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Canadian Psychiatric Assoc"],["dc.relation.issn","0706-7437"],["dc.title","Separation anxiety and actual separation experiences during childhood in patients with panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S0893-133X(02)00298-1"],["dc.bibliographiccitation.firstpage","270"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Neuropsychopharmacology"],["dc.bibliographiccitation.lastpage","278"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Koch, K."],["dc.contributor.author","Bartmann, U."],["dc.contributor.author","Kinkelbur, J."],["dc.contributor.author","Schweiger, U."],["dc.contributor.author","Hohagen, F."],["dc.contributor.author","Hajak, Goran"],["dc.date.accessioned","2018-11-07T10:17:13Z"],["dc.date.available","2018-11-07T10:17:13Z"],["dc.date.issued","2002"],["dc.description.abstract","Reduced 5-HT1A-receptor responsiveness has been reported in patients with panic disorder(PD) and/or agoraphobia 0 (PDA). Although many of these patients are regular smokers, it has not been examined whether psychological or neurobiological effects induced by the selective 5-HT1A-receptor agonist, ipsapirone, are affected by the smoking status of the patients. In order to clarify this question neuroendocrine challenges with oral doses of ipsapirone (0.3 mg/kg) and placebo were performed in 39 patients with PDA, and results were compared between patients who smoked (>10 cigarettes per day, n = 17) and patients who had been non-smokers for at least two years (n = 22). Patients who were smokers (but did not smoke during the challenge procedure) had significantly reduced baseline concentrations of cortisol and a significantly lower body temperature. In comparison to placebo, administration of ipsapirone was associated with significant increases of various psychological symptoms and plasma cortisol concentrations. The subgroup of PD patients who were smokers showed significantly higher cortisol responses to ipsapirone than non-smokers. In conclusion, smoking status has to be taken into account when assessing the responsiveness of 5-HT1A receptors in patients with psychiatric disorders. The prevention of smoking during challenge sessions might not be the ideal approach in heavy smokers, since sudden abstinence from smoking is likely to affect neurobiological and possibly psychological responses to ipsapirone."],["dc.identifier.doi","10.1016/S0893-133X(02)00298-1"],["dc.identifier.isi","000176402600014"],["dc.identifier.pmid","12093600"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41188"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0893-133X"],["dc.title","Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","831"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Neural Transmission"],["dc.bibliographiccitation.lastpage","837"],["dc.bibliographiccitation.volume","107"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:09:47Z"],["dc.date.available","2018-11-07T11:09:47Z"],["dc.date.issued","2000"],["dc.description.abstract","Background. Research on basal HPA axis activity in patients with panic disorder showed inconsistent results. Methods. Basal total plasma, plasma free and salivary cortisol levels were compared in patients with panic disorder (n = 47) and in healthy individuals (n = 23). Correlations between these fractions were calculated. Results. All three basal cortisol fractions were significantly elevated in patients compared to controls. There were significant correlations between all three cortisol fractions. Conclusions. Nonsignificant differences between cortisol levels of patients and healthy controls in previous studies may have been due to inclusion of less severely ill patients or to small sample sizes (96 words)."],["dc.identifier.doi","10.1007/s007020070062"],["dc.identifier.isi","000088415100008"],["dc.identifier.pmid","11005547"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53083"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0300-9564"],["dc.title","Salivary, total plasma and plasma free cortisol in panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","495"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Psychiatry"],["dc.bibliographiccitation.lastpage","500"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Sojka, Felicita"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Ruether, Eckart"],["dc.date.accessioned","2018-11-07T09:10:15Z"],["dc.date.available","2018-11-07T09:10:15Z"],["dc.date.issued","2006"],["dc.description.abstract","Background. - Earlier studies on the influence of pregnancy and postpartum period on the course of panic disorder have been inconsistent. The present study aims to quantify panic manifestations in these periods in large sample of women. Method. - Panic manifestations, including exacerbations and new manifestations of panic disorder, were assessed retrospectively in a sample of 128 women with panic disorder with or without agoraphobia, 93 of whom had had 195 pregnancies. Results. - Panic manifestations were fewer during pregnancy and more frequent in the postpartum period when compared with the control period. Women who had never been pregnant had significantly more panic manifestations than women with prior pregnancies. Breastfeeding and miscarriages did not have a significant effect. Women with postpartum panic reported more psychosocial stress events during this period. Conclusions. - Possible reasons for postpartum panic and the protective effects of pregnancy are discussed, including psychosocial or hormonal factors and other neurobiological changes. Postpartum panic coincides with a sudden drop of hormones after delivery. (c) 2006 Elsevier Masson SAS. All rights reserved."],["dc.identifier.doi","10.1016/j.eurpsy.2005.11.005"],["dc.identifier.isi","000241925900010"],["dc.identifier.pmid","16529913"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26446"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier France-editions Scientifiques Medicales Elsevier"],["dc.relation.issn","0924-9338"],["dc.title","Panic disorder during pregnancy and postpartum period"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","169"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Psychiatry Research"],["dc.bibliographiccitation.lastpage","179"],["dc.bibliographiccitation.volume","134"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Krause, Jan"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:08:29Z"],["dc.date.available","2018-11-07T11:08:29Z"],["dc.date.issued","2005"],["dc.description.abstract","Patients with borderline personality disorder (BPD) were have not yet been compared with a healthy control group with regard to traumatic life events during childhood. The patients (n = 66) and controls (n = 109) were investigated using a comprehensive retrospective interview with 203 questions about childhood traumatic life events, parental attitudes, family history of psychiatric disorders and birth risk factors. The frequency of reports of traumatic childhood experiences was significantly higher in patients than in controls, including sexual abuse, violence, separation from parents, childhood illness, and other factors. On a 0- to 10-point \"severe trauma scale,\" patients had significantly more severe traumatic events (mean score = 3.86, SD = 1.77) than control subjects (0.61, SD = 0.93). Only four (6.1%) of the BPD patients, but 67 (61.5%) of the controls did not report any severe traumatic events at all. Compared with controls, patients described the attitude of their parents as significantly more unfavorable in all aspects. Patients reported significantly higher rates of psychiatric disorders in their families in general, especially anxiety disorders, depression, and suicidality. Among birth risk factors, premature birth was reported more often in BPD subjects. In a logistic regression model of all possible etiological factors examined, the following factors showed a significant influence: familial neurotic spectrum disorders, childhood sexual abuse, separation from parents and unfavorable parental rearing styles. The present data support the hypothesis that the etiology of BPD is multifactorial and that familial psychiatric disorders and sexual abuse are contributing factors. © 2005 Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.psychres.2003.07.008"],["dc.identifier.isi","000228935500007"],["dc.identifier.pmid","15840418"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52793"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.issn","0165-1781"],["dc.title","Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","904"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","The World Journal of Biological Psychiatry"],["dc.bibliographiccitation.lastpage","913"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Weiss, Nina"],["dc.contributor.author","Engel, Kirsten"],["dc.contributor.author","Neubert, Karin"],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T08:38:05Z"],["dc.date.available","2018-11-07T08:38:05Z"],["dc.date.issued","2010"],["dc.description.abstract","Objectives. Regular aerobic exercise (running) has been shown to be superior to a pill placebo in the treatment of panic disorder. Combined drug and exercise treatment has not been investigated in randomized controlled studies to date. Methods. This is a randomized, 10-week, controlled, parallel group, pilot study. A total of 75 outpatients with panic disorder with or without agoraphobia (DSM-IV and ICD-10) received either (1) exercise plus paroxetine 40 mg/day (n = 21), (2) relaxation plus paroxetine (n = 17), (3) exercise plus pill placebo (n = 20), or (4) relaxation plus pill placebo (n = 17). Changes in the Panic and Agoraphobia Scale (P&A), and the Clinical Global Impression Scale (CGI) underwent repeated measure analysis. Results. Effects sizes were large for all groups (d = 1.53-3.87), however not significantly different. Paroxetine-treated patients were significantly more improved than placebo-treated patients. On the CGI, patients in the exercise groups (plus paroxetine or placebo) had a trend toward better improvement compared to relaxation (P = 0.06). Response and remission rates were higher in the paroxetine compared to pill placebo groups. Conclusions. While paroxetine was superior to placebo, aerobic exercise did not differ from relaxation training in most efficacy measures."],["dc.description.sponsorship","GlaxoSmithKline"],["dc.identifier.doi","10.3109/15622975.2010.489620"],["dc.identifier.isi","000282191400008"],["dc.identifier.pmid","20602575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18686"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1562-2975"],["dc.title","A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.volume","78"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Weiss, N."],["dc.contributor.author","Rotter-Glattkowski, P."],["dc.contributor.author","Engel, Katharina"],["dc.contributor.author","Neubert, K."],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T10:57:26Z"],["dc.date.available","2018-11-07T10:57:26Z"],["dc.date.issued","2007"],["dc.format.extent","510"],["dc.identifier.isi","000253318801496"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50250"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","0028-2804"],["dc.title","Controlled study for effectiveness of sport vs. relaxation training in combination with paroxetine vs. Placebo in the treatment of the panic disorder"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","269"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Comprehensive Psychiatry"],["dc.bibliographiccitation.lastpage","278"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Spath, C."],["dc.contributor.author","Tichauer, G. A."],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T10:20:06Z"],["dc.date.available","2018-11-07T10:20:06Z"],["dc.date.issued","2002"],["dc.description.abstract","Traumatic life events during childhood and parental attitudes are discussed as possible etiological factors for panic disorder (PD). Patients with PD (n = 115) and subjects without a history of psychiatric disorders (n = 124) were investigated using a comprehensive retrospective interview with 203 questions regarding childhood traumatic life events, parental attitudes, family history of psychiatric disorders, and birth risk factors. The frequency of reports of some traumatic childhood experiences was significantly different between patients and controls, including death of father, separation from parents, childhood illness, parents' alcohol abuse, violence in the family, sexual abuse, and other factors. On a 0 to 9 \"severe trauma scale\" patients had significantly more severe traumatic events (mean score, 1.31; SD 1.21) than control subjects (0.52; SD 0.80; P <.0001). Only 31.3% of the panic patients, but 62.9% of the controls, did not report any severe traumatic events at all (P <.0001). Compared to controls, patients described the attitude of their parents as more restricting and providing less loving care and attention. Patients reported significantly higher rates of psychiatric disorders in their families in general, in particular PD and generalized anxiety disorder. Birth risk factors did not differ significantly. In a logistic regression model, the following possible etiological factors showed a significant influence: family history of anxiety disorders, severe traumatic events during childhood, and unfavorable parental attitudes. The present data support the hypothesis that the etiology of PD is multifactorial and that traumatic life events may be a contributing factor. Owing to the retrospective nature of the data, the results have to be interpreted with caution. Copyright 2002, Elsevier Science (USA). All rights reserved."],["dc.identifier.doi","10.1053/comp.2002.33492"],["dc.identifier.isi","000176817300004"],["dc.identifier.pmid","12107864"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41806"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co"],["dc.relation.issn","0010-440X"],["dc.title","Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Neuropsychopharmacology"],["dc.bibliographiccitation.lastpage","164"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Meyer, T."],["dc.contributor.author","Opitz, M."],["dc.contributor.author","Bartmann, U."],["dc.contributor.author","Hillmer-Vogel, U."],["dc.contributor.author","George, A."],["dc.contributor.author","Pekrun, G."],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T10:39:09Z"],["dc.date.available","2018-11-07T10:39:09Z"],["dc.date.issued","2003"],["dc.description.abstract","Blunted neuroendocrine and physiological responses to the selective 5-HT1A receptor agonist, ipsapirone, have been observed in patients with panic disorder and/or agoraphobia (PDA). In order to examine whether this hyporesponsiveness to ipsapirone is modified by pharmacological or non-pharmacological therapeutic interventions, challenges with an oral dose of ipsapirone (0.3 mg/kg) and placebo were performed in patients with PDA before and after 10 weeks of treatment with clomipramine, aerobic exercise and placebo. Before treatment, administration of ipsapirone was followed by significant increases of cortisol, anxiety and other psychopathological symptoms in comparison to the placebo challenge. In addition, a significant decrease of body temperature was observed. After the 10-week treatment period, the psychological responses to ipsapirone were significantly reduced in the clornipramine and the exercise group. In contrast, there was a non-significant trend towards higher cortisol responses after clornipramine and exercise treatment. The hypothermic response to ipsapirone was significantly reduced by clornipramine treatment. In conclusion, our results demonstrate that effective treatment of panic disorder has divergent effects on the psychological, neuroendocrine and temperature responses to ipsapirone. (C) 2003 Elsevier Science B.V./ECNP All rights reserved."],["dc.identifier.doi","10.1016/S0924-977X(02)00177-3"],["dc.identifier.isi","000183090600003"],["dc.identifier.pmid","12729940"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45977"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0924-977X"],["dc.title","5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","17"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Fortschritte der Neurologie · Psychiatrie"],["dc.bibliographiccitation.lastpage","24"],["dc.bibliographiccitation.volume","68"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Junghanns, K."],["dc.contributor.author","Thiel, A."],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T11:05:30Z"],["dc.date.available","2018-11-07T11:05:30Z"],["dc.date.issued","2000"],["dc.description.abstract","During the last decade several new agents have been introduced in the treatment of depressive disorders. In comparison to classical tricyclic antidepressants, these agents have less side effects and a very low toxicity. Selective inhibitors of serotonin reuptake do not produce sedation; however, in the initial phase of treatment this is not always an advantage. In contrast, receptor antagonists, such as mirtazapin and nefazodone have moderate sleep-inducing properties. Selective agents are also characterized by certain pharmacologic interactions which can lead to considerable inhibition of the metabolism of other drugs. Classical antidepressants still play an important role in the treatment of severe depressive episodes. Different synaptic effects of new antidepressants lead to an increased availability of monoaminergic neurotransmitters. The article summarizes the most important neurobiological consequences of these acute synaptic effects which might be more closely associated with neurobiological correlates of depression. The authors conclude about the advantages and disadvantages of the different classes of antidepressants from a clinical point of view."],["dc.identifier.doi","10.1055/s-2000-11639"],["dc.identifier.isi","000085143600003"],["dc.identifier.pmid","10705571"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52080"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1439-3522"],["dc.relation.issn","0720-4299"],["dc.title","Advances in the pharmacotherapy of depression by new antidepressants"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]